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BACKGROUND: Therapeutic plasma exchange (TPE)
is increasingly used for treatment of antibody-mediated
rejection (AMR) after solid organ transplants. There is
concern that TPE may increase risk of bleeding, although
data are limited. After TPE, clot-based coagulation tests
may not accurately represent the levels of coagulation
factors due to the effect of citrate. We investigated
protein levels of fibrinogen using antigen detection
method (FibAg) and correlated results with a clot-based
fibrinogen activity test (Fib).
STUDY DESIGN AND METHODS: Nine kidney
transplant recipients who received TPE for AMR were
investigated. Fib, FibAg, prothrombin time/international
normalized ratio (PT/INR), partial thromboplastin time
(PTT), coagulation factor X chromogenic activity (CFX),
and ionized calcium (iCa) were measured at pre- and
post-TPE and 1, 3, 6, 9, 24, and 48 hours after the first
TPE.
RESULTS: Mean Fib/FibAg ratio before TPE was 1.08;
therefore, all Fib values were normalized (n) by dividing
by 1.08. Overall, the mean normalized Fib (nFib)/FibAg
ratio at post-TPE was 0.89 and returned to close to 1.0 at
6 hours after the first TPE. Decreases in nFib, FibAg, and
CFX and increases in PT/INR and PTT post-TPE were
observed. The lowest Fib, FibAg, CFX, platelet, and iCa
levels were still at levels that would be considered
sufficient for hemostasis at all time points.
CONCLUSION: The mean nFib/FibAg ratio after TPE
was 0.89 and normalized in 6 hours, which demonstrates
a persistent effect of citrate for up to 6 hours. Therefore,
similar data observed in clot-based tests of PT/INR and
PTT may be falsely elevated up to 6 hours after TPE due
to the citrate effect.
I
n recent years, therapeutic plasma exchange (TPE),
combined with immunomodulation, has been
increasingly used for treatment of antibody-
mediated rejection (AMR), especially in kidney trans-
plant recipients. At our institution, many patients start
TPE shortly after the histologic diagnosis of AMR, and the
occurrence of bleeding complications after kidney allo-
graft biopsy in the period of 2010 to 2011 was five times
higher in patients who received TPE than in patients who
did not receive TPE, 1.03% in all patients versus 5.17% in
patients who received TPE within 5 days of the biopsy
(unpublished data, courtesy of nephrology service at our
institution). One of the possible causes of this can be coa-
gulopathy after TPE procedures. The most commonly
used coagulation tests, including prothrombin time/inter-
national normalized ratio (PT/INR), partial thromboplas-
tin time (PTT), coagulation factor assays, and fibrinogen
ABBREVIATIONS: AMR 5 antibody-mediated rejection;
CFX 5 coagulation factor X chromogenic activity; Fib 5
fibrinogen activity; FibAg 5 fibrinogen antigen; iCa 5
ionized calcium; INR 5 international normalized ratio;
nFib 5 normalized fibrinogen; PT 5 prothrombin time;
PTT 5 partial thromboplastin time; TBV 5 total blood
volume; TPE 5 therapeutic plasma exchange.
From the 1Department of Pathology, the 2Department of
Pediatrics/Pathology, the 3Department of Biostatistics, the
4Department of Internal Medicine, and the 5Department of
Surgery, University of Michigan, Ann Arbor, Michigan.
Address reprint requests to: Chisa Yamada, MD, Department
of Pathology, Blood Bank/Transfusion Medicine, University of
Michigan, 1500 E. Medical Center Drive, SPC 5054, 2F228 UH,
Ann Arbor, MI 48109-5054; e-mail: yamadac@med.umich.edu.
A University of Michigan Pathology internal grant sup-
ported laboratory tests and study coordinators’ fees.
Received for publication May 12, 2016; revision received




Volume 56, December 2016 TRANSFUSION 3073
activity (Fib) are based on clotting time and are influenced
by the presence of citrate, which is used for TPE proce-
dures. Consequently, these laboratory tests may represent
a patient’s coagulation status, but they may not accurately
represent the concentration of coagulation factors. Addi-
tionally, abnormal coagulation test results in this scenario
may trigger the unnecessary use of plasma or cryoprecipi-
tate transfusion.
The decrease of coagulation factors and Fib using
clotting time–based assays (PT/INR, PTT) after TPE has
been described.1,2 However, the decrease of protein levels
of fibrinogen has not been reported thus far. Therefore,
we conducted a prospective investigation of fibrinogen
quantity using fibrinogen antigen (FibAg) detection meth-
odology and correlated these results with widely used
clot-based Fib tests over the time in patients with AMR of
kidney transplants treated with TPE within several days
after the biopsy. Additionally, we investigated PT/INR,
PTT, coagulation factor X chromogenic activity (CFX), ion-
ized calcium (iCa), and platelet (PLT) count over time and
correlated these data with clinical outcome.
MATERIALS AND METHODS
We obtained financial support from the University of
Michigan Department of Pathology, and the study was
approved by the University of Michigan Institutional
Review Board. Potential subjects were identified by neph-
rologists or transfusion medicine physicians and consent
was obtained by participating study coordinators. We
recruited adult renal transplant recipients with AMR who
were scheduled to receive TPE followed by IVIG per our
institutional protocol for participation in the study. Exclu-
sion criteria included children (younger than age 18 years
old), patients with elevated liver function tests (reference
range at our institution, AST 8-30 IU/L, ALT 7-35 IU/L),
pregnant patients, mentally impaired patients, and
patients who did not provide informed consent. If a
patient developed any signs of bleeding such as hemato-
ma or hematuria within 48 hours after the first TPE, the
patient was discontinued from study participation and
received appropriate treatment. The study was not
designed to alter any standard care; therefore, the labora-
tory test results only for the study purposes were blinded
to treating physicians and the study team.
TPE procedure
Patients received TPE between three and six times
depending on the patient’s donor-specific antibody level
measured by Luminex-based technology (One Lambda,
Thermo-Fisher Scientific, Inc.) as mean fluorescence
intensity. Each procedure was performed with one plasma
volume exchange, and the replacement fluid consisted of
5% albumin only or 5% albumin and plasma (up to half
plasma volume) when TPE was performed within 5 days
of biopsy according to our institutional protocol for AMR
treatment of kidney transplant recipients. When plasma
was used, the plasma dose was recorded. Citrate (ACD-A)
was infused in blood draw line during the TPE procedure
at the rate of 0.8 mL/min/L total blood volume (TBV) for
both albumin and plasma replacement procedures. The
amount of citrate was determined by an apheresis
machine (Optia or Spectra, both TerumoBCT), with each
patient’s TBV calculated based on sex, height, and weight
to meet the set infusion rate of 0.8 mL/min/L TBV. There-
fore, the citrate infusion rate in all patients was constant.
Calcium was added to all albumin bottles (1.2 mmol sup-
plementation per 500 mL) for replacement and provided
more in normal saline into their return line if the patients
showed citrate toxicity or when plasma was used as a
replacement, and the dose of total calcium supplementa-
tion was recorded.
Laboratory testing
Standard protocol orders for AMR treatment were made
by the primary nephrology team. The schedule for labora-
tory tests follows: Fib and FibAg, PT/INR/PTT, CFX, and
iCa were determined immediately before TPE (Pre-TPE),
immediately after TPE (Post-TPE), and 1, 3, 6, 9, 24, and
48 hours after the first TPE; PLT count was obtained
before TPE (within the same day), Post-TPE, and 24 hours
after the first TPE. Additional blood draws for all parame-
ters were obtained before third and fourth TPE procedures
for the last three patients. The acceptable timing of sched-
uled blood draws except Pre- and Post-TPE was within 15
minutes for the 1- and 3-hour time points after the TPE
and within 2 hours thereafter. All blood samples were dei-
dentified and a study identifier was assigned to each sub-
ject. Fib, FibAg, PT/INR, PTT, CFX, iCa, and PLT results
other than the tests performed as a standard care were
held by the hematology and chemistry laboratory direc-
tors or supervisors to ensure blinding of the results and to
avoid alteration of standard treatment due to test results.
Those test results were unblinded after the last subject
had completed the study. The test results performed as
standard care were retrieved from the electronic medical
record.
Clinical data collection
Each subject’s age, sex, preprocedure use of anticoagu-
lants, clinical, laboratory, and TPE procedural data were
retrieved from the electronic medical record and recorded.
After the last subject completed the study, all bleeding or
thrombotic events noted by the primary nephrology team
within 1 month after the last TPE procedure were
retrieved from the electronic medical record. Information
regarding bleeding and blood product transfusion was
also obtained when applicable.
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Statistical analysis
The correlation of Fib and FibAg was analyzed at each
time point. The mean Fib/FibAg ratio before TPE (in the
absence of any citrate effect) was 1.08, indicating that Fib
results in 8% higher than FibAg. Therefore, all Fib results
were normalized (n) by dividing by 1.08 to compensate for
the difference of the test methods. All data were also
divided into three groups, all patients, and patients with
and without plasma replacement use depending on the
days after the biopsy to see the effect of plasma use on
each parameter. Extreme outliers in coagulation test
results were considered to be not clinically plausible and
likely due to heparin contamination of samples drawn
through central catheters or soon after the regular antico-
agulant dose. Therefore, data that were greater than 2
standard deviations (SDs) from the mean for each study
parameter and also far different from other data in the
same patient representing possible anticoagulant contam-
ination (such as PTT > 100 sec with a mean of 23 sec)
were excluded from the analysis.
A linear mixed-effects regression model was used to
assess changes of each parameter over the time. Specifi-
cally, we modeled the parameter as a piecewise linear
function of time, with a change point fixed at the post-
TPE time point. Slopes before and after the change point
were then tested to determine whether they are different
from the post-TPE time point. Significance was deter-
mined at a p value of less than 0.05. All analyses were con-
ducted using computer software (SAS, Version 9.4, SAS
Institute).
RESULTS
Eleven patients consented to the study. One patient was
found to be pregnant after the consent was obtained and
was excluded, and one patient withdrew the consent.
Thus, the analysis was performed in nine subjects (A-I).
Age ranged from 19 to 67 years old (median, 41 years old),
six males and three females (Table 1). Table 1 also shows
anticoagulant use, use of plasma as a percentage of total
replacement fluid volume, and the dose of calcium
supplementation during TPE. The prescribed anticoagu-
lants were not altered during the course of TPE treatment.
One patient on low-molecular-weight heparin had much
lower CFX level only at the pre-TPE time point than CFX
levels at other time points after TPE (more than 70% low-
er); therefore, these data were excluded from analysis.
Two data points in PT/INR and two data points in PTT
were far above 2 SDs and were excluded from the data
analysis due to possible anticoagulant contamination.
Table 2 shows mean and range of test results in each
parameter at Pre- and Post-TPE. The mean level change
(%) of normalized Fib (nFib), FibAg, CFX, PT/INR, and
PTT based on the pre-TPE level at each time point are
shown in Figs. 1A-1F. All figures show level change in three
groups: all patients, patients with plasma replacement,
and without plasma replacement.
The nFib/FibAg ratio at each time point in each
patient is shown in Table 3. The mean change of nFib/
FibAg ratio at each time point based on pre-TPE level in
the same three groups above is shown in Fig. 2. Overall,
nFib/FibAg ratio decreased immediately after TPE and
returned to the pre-TPE level in 6 hours. However, this
ratio returned to pre-TPE level in 3 hours after TPE in the
patient group with plasma replacement, and the ratio did
not return to pre-TPE level in the patient group without
plasma replacement although returning slope was
observed toward 6-hour time point.
Significance (p value) of level decrease or increase
before TPE and after post-TPE time points in all patients
is shown above each graph in Figs. 1 and 2. p values of the
slope before and after the Post-TPE time point in each
TABLE 1. Demographics, TPE procedure data, and anticoagulant use
Patient Age (years) Sex




A 67 Female 29.4 6.1 Warfarin, low-dose aspirin
B 19 Male 45.7 10.5 Low-molecular-weight heparin
C 63 Male 0 7.2 Heparin
D 23 Male 32.4 6.0
E 37 Male 0 6.0
F 52 Male 19.4 9.1 Low-dose aspirin
G 65 Male 0 9.6
H 40 Female 0 6.9
I 41 Female 19.4 11.2
TABLE 2. Mean and range value of each parameter at
pre- and post-TPE time points
Variable Pre-TPE Post-TPE
Fib (mg/dL) 412.0 (339-465) 187.0 (110-293)
FibAg (mg/dL) 392.25 (326-513) 194.89 (135-235)
PT (sec) 11.4 (10.6-13.8) 13.53 (11.4-16.4)
INR 1.09 (1.0-1.4) 1.31 (1.1-1.6)
PTT (sec) 26.04 (21.4-33.3) 29.76 (25.5-34.4)
CFX (%) 149.11 (110-293) 68.56 (40-93)
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parameter in three groups (all patients and patients with
and without plasma replacement) are shown in Table S1
(available as supporting information in the online version
of this paper). Overall, nFib, FibAg, and CFX showed a sig-
nificant decrease after TPE, but only nFib showed signifi-
cance in returning slope to the pre-TPE level. Increasing
slope toward Post-TPE time point and returning slope
were significant in PT/INR, but not significant in PTT.
Decrease of nFib/FibAg ratio toward post-TPE was not
statistically significant; however, the return was signifi-
cant. Between two groups, patients treated with and with-
out plasma replacement, the differences of level change
were not significant for nFib, FibAg, nFib/FibAg ratio, and
CFX, but were significant for PT and PTT (Table 4).
iCa was from 0.97 to 1.45 mmol/L with one exception
of 0.3 mmol/L with INR of 1.2 at Post-TPE in one patient
whose iCa returned to 1.32 mmol/L at 1 hour after TPE
(Fig. 3). PLT count ranged from 105 3 109 to 305 3 109/L.
Percentage of nFib, FibAg, CFX, and PLTs based on
the pre-TPE level before the second (48 hr), third (96 hr),
and fourth (144 hr) TPE procedures from three patients
who were not on any anticoagulant is shown in Table 5.
No trending decrease was observed in any of the parame-
ter after the second TPE procedure.
Two patients had bleeding episodes after TPE treat-
ment. One patient on warfarin had bloody bowel
movements from existing nonthrombosed external hem-
orrhoids observed by flexible sigmoidoscopy 6 days after
the first TPE procedure, 1 day after the third TPE
Fig. 1. The mean level change (%) based on pre-TPE level at each time point. (A) nFib; (B) FibAg; (C) CFX; (D) PT; (E) INR; (F)
PTT. All data are shown in three groups, all patients (—), patients with plasma replacement use for TPE (– – –), and patients
without plasma replacement use for TPE (  ). Significance (p value) of level change before and after the post-TPE time point in
all patients (both patients with and without plasma replacement) is shown above each graph. p value on the left above each
graph is level decrease or increase before Post-TPE time point and that on the right is level increase or decrease after Post-TPE
time point. Significance was determined if the p value was less than 0.05.
TABLE 3. nFib/FibAg ratio at each time point in each
patient
Patient Pre Post 1 hr 3 hr 6 hr 9 hr 24 hr 48 hr
A 1.02 0.99 0.93 1.09 1.22
B 0.83 0.89 0.70 1.04
C 1.17 0.88 0.89 0.79 0.79 0.81 0.76 0.89
D 0.99 0.96 0.71 0.82 0.99 0.97 1.15 0.88
E 1.22 0.96 1.12 1.26 1.36 1.00 1.26
F 1.07 1.22 1.21 1.35 1.30 1.21 1.32 0.83
G 0.92 0.76 0.76 0.88 0.95 0.95 1.06 0.82
H 0.61 0.43 0.56 0.42 0.61 1.06 0.82 1.24
I 0.97 0.99 1.02 1.13 1.10 1.20 1.02
Mean 1.00 0.89 0.90 0.92 1.01 1.00 1.05 1.02
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procedure. This patient received a transfusion of 1 unit of
plasma and iron supplementation for hemoglobin (Hb)
level of 9.0 g/dL. The patient’s Hb level remained stable
with no further bleeding. The other patient had heavy
menses 7 days after the last TPE procedure, in the setting
of irregular menstrual cycles and possible leiomyoma.
This patient did not receive any transfusion.
DISCUSSION
The higher likelihood of bleeding complication after inva-
sive procedures in patients receiving TPE is a concern in
patients who are undergoing AMR treatment. Percutaneous
renal biopsy is a well-established procedure and the
occurrence rate of bleeding complications such as hemato-
ma and hematuria ranges from 1.0% to 33.3% (>90% clini-
cally silent) and from 3.0% to 9.9%, respectively, in the
literature.3-6 TPE may increase the risk of bleeding by
removal of coagulation factors or by the anticoagulant effect
of citrate. One-plasma-volume TPE decreases plasma pro-
tein levels by approximately 65%.7 One study showed that
Fib decreased by a mean of 42% and other coagulation fac-
tors decreased between 22.7 and 55.3% immediately after
the TPE; however, the absolute concentrations remained
within or only slightly below the reference range.1 At our
institution, at least 10 mL/kg plasma is used as a replace-
ment fluid for TPE to add coagulation factors in patients
within 5 days of their biopsies. Thus, increased bleeding risk
due to depletion of coagulation factors would not generally
be expected.
Calcium is one of the cofactors in the coagulation
cascade and is required by seven vitamin K–dependent
coagulation factors. Citrate used during TPE binds to cir-
culating divalent cations, including Ca21 and Mg21, in the
blood, leading to a decrease in 10% to 15% of iCa concen-
tration.8 This reduction in iCa slows the process of coagu-
lation cascade and reduces PLT aggregation and
fibrinogen binding,9 and prevents clotting in the extracor-
poreal circuit during TPE. However, reduced iCa may
exacerbate the effect of TPE-related decrease of coagula-
tion factors, leading to a coagulopathic status and
increased susceptibility to bleeding after the TPE until the
citrate effect is diminished by normal metabolism.
Strauss10 calculated that the 15 to 24 mmol/L citrate levels
achieved within cell separation circuits during a typical
apheresis procedure would lower the iCa below 0.2 to 0.3
mmol/L. Since all our participants received Ca supple-
mentation into their return lines, the post-TPE iCa value
in most patients was only slightly decreased (Fig. 3). How-
ever, the dose of Ca supplementation was not constant in
TABLE 4. Significance (p value) of difference
between with and without plasma replacement
before and after Post-TPE time point
Change Parameter p value
















Fig. 2. The mean change of nFib/FibAg ratio (%) based on
pre-TPE level at each time point. The data are also shown in
the same three groups as those in Fig. 1. p value is also
shown in the same manner as Fig. 1.
Fig. 3. iCa values at each time point in each patient. The
data of each patient are shown in different line type.
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each patient with variable Ca infusion rates during each
procedure, the distribution and elimination of Ca may not
be constant in our patients who had variable degrees of
renal insufficiency, the duration of each TPE procedure
was not constant, and additional citrate from plasma was
administered when plasma was used for replacement.
Therefore, iCa data may not be meaningful to evaluate cit-
rate level at the post-TPE time point. In fact, nFib/FibAg
ratio, nFib levels, or INR did not show correlation with iCa
levels in six patients for whom iCa data were available at
the post-TPE time point (Fig. S1, available as supporting
information in the online version of this paper). Notably,
the iCa level in one patient at the post-TPE time point was
0.3 mmol/L with an INR value of 1.2. This patient received
albumin replacement at first with constant Ca supple-
mentation in the albumin bottle and plasma replacement
at the end of TPE with some additional Ca supplement in
normal saline (total, 11.2 mmol Ca supplementation).
This case most likely suggests that the citrate dose was
enough to decrease iCa, but Ca supplementation at the
end of TPE was insufficient to completely overcome this
effect. Furthermore, the INR level at the post-TPE time
point did not reflect low iCa level, suggesting that a tem-
porally low iCa level may not be clinically important.
Fibrinogen is most commonly measured by the Fib
test, by determining the clotting time of diluted plasma
after the addition of thrombin. The clotting endpoint is
compared to a standard reference curve and the fibrino-
gen concentration is determined. With the presence of cit-
rate, the clotting time will be prolonged, and thus the Fib
result will be lower. On the other hand, the FibAg test is
performed by radial immunodiffusion and detects FibAg-
antibody complex using an agarose gel containing an anti-
body specific for fibrinogen. Antigen-antibody complexes
will form a precipitin ring and the ring size is proportional
to the antigen concentration. Thus, the results of this test
are not altered by the presence of citrate.
In our limited number of participants, the Fib result
was on average 11% lower than the FibAg test result
immediately after TPE and returned close to equivalent in
6 hours (Table 3, Fig. 2). These data suggest a citrate effect
on Fib measurements, although the changes of the nFib/
FibAg ratio at any time point (p > 0.7125, data not shown)
and the decrease of the nFib/FibAg ratio (p 5 0.3738, Fig.
2) were not significant. Similarly, any tests reliant on calci-
um may be affected by citrate; therefore, CFX may be
falsely lower and PT/INR and PTT may be falsely higher
up to 6 hours after TPE. We found that PTT also returned
to the pre-TPE level at the 6-hour time point overall.
The lowest Fib, FibAg, CFX, PLT count, and iCa were
110 mg/L, 134 mg/L, 40%, 107 3 109/L, and 0.97 mmol/L
(except for one patient discussed above), respectively (at
the post-TPE time point), which should be sufficient to
maintain hemostasis. However, all nFib, FibAg, and CFX
levels did not return to pre-TPE level within 48 hours (Fig.
1), which may raise a possibility of further decreases with
frequent TPE. The percentage of nFib, FibAg, CFX, and
PLT count based on the pre-TPE levels before second,
third, and fourth TPE procedure did not show progressive
decline (Table 5) in data from three patients without anti-
coagulants. One patient among these three patients
received plasma replacement only in the first TPE. These
data were not affected by citrate because subsequent TPE
procedures were performed at around 48 hours after each
TPE, given that the citrate effect appears to last for 6 hours
from our study. This observation suggests that coagulation
factors decreased by TPE return to their pre-TPE level in 2
days after the second TPE. Therefore, plasma or cryopreci-
pitate transfusion is not required even with multiple pro-
cedures when TPE procedures are performed every other
day or less frequently. A previous report had a similar find-
ing.1 Blasi and colleagues11 showed that fibrinogen levels
before the first TPE procedure and the second TPE proce-
dure (1 or 2 days after the first TPE procedure) were simi-
lar albeit with reduced clot firmness that was without
clinical implications. However, our results are based on a
limited number of patients and a larger study is necessary
to confirm this observation, especially since we found that
fibrinogen recovery was slightly delayed relative to CFX.
When two groups, patients with and without plasma
replacement use, were compared, nFib, FibAg, nFib/FibAg
ratio, and CFX did not show significant differences (Table
4), which may also suggest plasma use for replacement
may not improve coagulation status after the TPE proce-
dure under the effect of citrate. However, PT and PTT
showed a significant difference in these two groups, with
the level increase toward Post-TPE time point greater in the
patient group without plasma replacement. This may be
due to PT and PTT being relatively sensitive to coagulation
factor levels below 50%; these test results might be affected
by a clinically nonsignificant decrease of coagulation fac-
tors to between 20 and 50% of reference range after TPE.
Coagulation factor VIII may require more than 30% of nor-
mal for normal hemostasis, while other coagulation factors
likely provide sufficient hemostasis at 10% to 20% of nor-
mal.12 However, our study showed that the lowest CFX was
40% (32.8% of pre-TPE level) even with the citrate effect.
Therefore, all coagulation factors should be more than 30%
of normal unless Pre-TPE levels were also lower. Thus, PT/
TABLE 5. Mean percentage of coagulation factors
based on pre-TPE level before subsequent TPE








nFib 100 42.45 60.05 58.04
FibAg 100 37.73 32.79 37.09
CFX 100 56.81 50.77 49.32
PLT 100 89.62 80.52 75.19
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INR and PTT may be increased more in patients without
plasma use due to some coagulation factors of less than
50% of normal, although the amount of coagulation factors
is likely sufficient for hemostasis in both groups.
Limitations of this study are the small number of par-
ticipants with some missing data and the potential con-
founding effect of systemic anticoagulation in some
patients and the possible contamination of some samples
by heparin used for central line flushing. Therefore, the
data from only patients who were not on anticoagulants
were also analyzed. nFib/FibAg ratio and CFX over time
for those patients demonstrated similar results between
all patients and patients without anticoagulants (Fig. S2,
available as supporting information in the online version
of this paper). Therefore, overall analysis was performed
using all patients’ data.
Finally, two patients had bleeding episodes from sites
other than kidney biopsy within several days after TPE.
However, these episodes were unlikely related to either
citrate or TPE effect, but rather related to the patients’
underlying conditions.
In summary, we found a difference between nFib and
FibAg levels up to 6 hours after TPE, although not signifi-
cant, which suggests a persistent citrate effect for this
period. Similarly, any tests reliant on calcium may be
affected by citrate; CFX may be falsely lower, and PT/INR
and PTT may be falsely higher, up to 6 hours after TPE.
Both FibAg and CFX did not return to pre-TPE levels in 48
hours after the first TPE procedure; however, the levels of
FibAg and CFX before the subsequent TPE did not show a
tendency for progressive decline. In addition, FibAg, CFX,
and PLTs showed sufficient levels to maintain coagulation
status at all time points observed, even in the presence of
a putative citrate effect. Therefore, blood component
transfusion is not necessary for coagulation factor
replacement when TPE is performed every other day or
less frequently, even though the patients can be coagulo-
pathic due to citrate effect up to 6 hours after TPE. Fur-
thermore, nFib, FibAg, and CFX results did not show a
significant difference between patients with and without
plasma replacement use, which may suggest that plasma
use as a replacement fluid up to 45% of total replacement
volume may not have any effect on coagulation status. A
larger study may be necessary to confirm these findings.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Table S1. Statistical significance (p value) of level
change before and after post-TPE time point
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Fig. S1. nFib†/FibAg‡ (normalized fibrinogen activity
test result/fibrinogen antigen test result) ratio, nFib,
INR and iCa# (ionized calcium) levels at post-TPE (ther-
apeutic plasma exchange)
Fig. S2. The mean level change (%) based on pre-TPE*
level at each time point on patients without
anticoagulants. A) nFib†/FibAg‡ ratio. B) CFX§ (coagu-
lation factor X chromogenic activity) test result. The
data are shown in 3 groups, all patients (—), patients
with plasma replacement use for TPE (– – –), and
patients without plasma replacement use for TPE
(  ).
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